Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.
ImpediMed will release its Appendix 4C quarterly cash flow report for the period ending 31 December 2025 on 29 January 2026 and will host an investor webinar the same day, led by CEO and Managing Director Dr Parmjot Bains and CFO and Executive Director McGregor Grant. The session, which requires pre‑registration via the company’s investor hub, will feature a management presentation followed by a live Q&A, signalling an ongoing effort to maintain transparent engagement with shareholders around the company’s financial performance and outlook.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited (ASX: IPD) is an Australian medical technology company focused on bioimpedance spectroscopy devices and related digital tools used in clinical settings, with a particular emphasis on measuring and managing fluid status in patients, including those at risk of lymphoedema and other fluid-related conditions.
YTD Price Performance: -2.94%
Average Trading Volume: 1,073,131
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$67.28M
Learn more about IPD stock on TipRanks’ Stock Analysis page.